Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 13/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.42 |
| ▸ | PLK1 | P53350 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | INSR | P06213 | 2/20 | 0.34 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | FYN | P06241 | 2/20 | 0.34 |
| ▸ | YES1 | P07947 | 2/20 | 0.34 |
| ▸ | LYN | P07948 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | ROS1 | P08922 | 2/20 | 0.34 |
| ▸ | KIT | P10721 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.34 |
| ▸ | FLT1 | P17948 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19633355 | 0.96 | FGFR1 (0.42) | FGFR1FGFR3FGFR4FGFR2PLK1 | |
| SCHEMBL19633296 | 0.92 | FGFR1 (0.43) | FGFR1FGFR3FGFR4FGFR2PLK1 | |
| SCHEMBL19633582 | 0.89 | FGFR1 (0.44) | FGFR1FGFR3FGFR4FGFR2JAK2 | |
| SCHEMBL28611756 | 0.89 | FGFR1 (0.37) | FGFR1FGFR3FGFR4FGFR2PLK1 | |
| SCHEMBL20836806 | 0.88 | FGFR1 (0.40) | FGFR1FGFR3FGFR4FGFR2PLK1 | |
| SCHEMBL30745814 | 0.88 | FGFR1 (0.40) | FGFR1FGFR3FGFR4FGFR2PLK1 | |
| SCHEMBL20836828 | 0.88 | FGFR1 (0.42) | FGFR1FGFR3FGFR4FGFR2PLK1 | |
| SCHEMBL19633581 | 0.87 | FGFR1 (0.55) | FGFR1FGFR3FGFR4FGFR2JAK2 | |
| SCHEMBL26802384 | 0.87 | FGFR3 (0.37) | FGFR1FGFR3FGFR4FGFR2JAK2 | |
| SCHEMBL30745796 | 0.87 | FGFR1 (0.33) | FGFR1FGFR3FGFR4FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358898-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2025-07-15 | — | — | US | disclosed |
| US-20240018130-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018130-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-11827625-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. | 2023-11-28 | — | — | US | disclosed |
| US-11827625-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. | 2023-11-28 | — | — | US | disclosed |
| EP-3459952-B1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE | ZHEJIANG HISUN PHARM CO LTD (CN) | 2022-01-05 | — | — | EP | disclosed |
| US-20210221797-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2021-07-22 | — | — | US | disclosed |
| US-11001572-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. | 2021-05-11 | — | — | US | disclosed |
| US-20200207745-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2020-07-02 | — | — | US | disclosed |
| US-10654836-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2020-05-19 | — | — | US | disclosed |
| WO-2017198221-A1 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE | 浙江海正药业股份有限公司 | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207745-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | FGFR4, FGFR1, FGFR2 | FGFR1 2/4885FGFR3 4/4885FGFR4 1/4885 |
| US-11827625-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | FGFR4, FGFR1, FGFR2 | FGFR1 2/4885FGFR3 4/4885FGFR4 1/4885 |
| US-12358898-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | FGFR4, FGFR1, FGFR2 | FGFR1 2/4885FGFR3 4/4885FGFR4 1/4885 |
| US-10654836-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | FGFR4, FGFR1, FGFR2 | FGFR1 2/4885FGFR3 4/4885FGFR4 1/4885 |
| US-20240018130-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | FGFR4, FGFR1, FGFR2 | FGFR1 2/4885FGFR3 4/4885FGFR4 1/4885 |
| US-20210221797-A1 | Pyrimidine Derivative, Method For Preparing Same And Use Thereof In Medicine | FGFR4, FGFR1, FGFR2 | FGFR1 2/4885FGFR3 4/4885FGFR4 1/4885 |
| US-11001572-B2 | Pyrimidine derivative, method for preparing same and use thereof in medicine | FGFR4, FGFR1, FGFR2 | FGFR1 2/4885FGFR3 4/4885FGFR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.